Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
31.2M
-
Number of holders
-
64
-
Total 13F shares, excl. options
-
4.75M
-
Shares change
-
+249K
-
Total reported value, excl. options
-
$44.9M
-
Value change
-
+$1.73M
-
Put/Call ratio
-
1.16
-
Number of buys
-
37
-
Number of sells
-
-26
-
Price
-
$9.45
Significant Holders of Actinium Pharmaceuticals, Inc. - Common Stock (ATNM) as of Q1 2023
79 filings reported holding ATNM - Actinium Pharmaceuticals, Inc. - Common Stock as of Q1 2023.
Actinium Pharmaceuticals, Inc. - Common Stock (ATNM) has 64 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 4.75M shares
of 31.2M outstanding shares and own 15.21% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (1.28M shares), BlackRock Inc. (547K shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (245K shares), GEODE CAPITAL MANAGEMENT, LLC (232K shares), MILLENNIUM MANAGEMENT LLC (231K shares), DIMENSIONAL FUND ADVISORS LP (180K shares), Sentinus, LLC (149K shares), TWO SIGMA ADVISERS, LP (134K shares), JANE STREET GROUP, LLC (124K shares), and RENAISSANCE TECHNOLOGIES LLC (102K shares).
This table shows the top 64 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.